DIA Jumps on Brexit Bandwagon
The considerable uncertainty caused by Brexit is proving a goldmine for conference organizers, it seems. The Drug Information Association (DIA) is the latest group to put together a meeting about this hot topic.
“Brexit will have a considerable impact on the regulation and supply of medicines to patients,” noted the DIA in a statement. “With the time frame for Brexit fast elapsing, governments, regulators, companies, healthcare systems, and patients are all seeking to prepare for the “known unknowns” and to brace for the “unknown unknowns”. However, information is scarce and not always accessible or confirmed.”
At its meeting to be held in London on December 8, DIA plans to bring stakeholders together to share their knowledge about operational and strategic measures being taken to prevent or minimize the impact of Brexit.
According to the organizers, “With the clock ticking, stakeholders will consider explicitly in this conference the dimension of time in shaping what opportunities for action companies-and indeed all stakeholders-must consider.”
The closing session, called Brexit time check: "what’s next for medicines?”, will be chaired by ACT columnist Peter O’Donnell. The aim is to investigate the broader level vision of what’s coming next in the Brexit schedule of change.
For the full program and further details, click here.
Philip Ward is the European Editor for Applied Clinical Trials.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
